BRD4 Amplification Facilitates an Oncogenic Gene Expression Program in High-Grade Serous Ovarian Cancer and Confers Sensitivity to BET Inhibitors

PLoS ONE - United States
doi 10.1371/journal.pone.0200826
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

Correction: Enhanced GAB2 Expression Is Associated With Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Molecular Cancer Therapeutics
Cancer ResearchOncology
2017English

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2014English

Amplification of the Ch19p13.2 NACC1 Locus in Ovarian High-Grade Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2011English

GLUT 1 Receptor Expression and Circulating Levels of Fasting Glucose in High Grade Serous Ovarian Cancer

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2017English

Integrated Analysis to Identify Molecular Biomarkers of High-Grade Serous Ovarian Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

VISTA Expression Is Associated With a Favorable Prognosis in Patients With High-Grade Serous Ovarian Cancer

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy